Lenvatinib combined with sintilimab plus transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma

Table 3 common treatment-related adverse events, n (%)

Adverse events	Grade 1/2	Grade 3/4	Any grade
Fatigue	13 (32.5)	0	13 (32.5)
Anorexia	5 (12.5)	0	5 (12.5)
Leukocytopenia	15 (37.5)	0	15 (37.5)
Increased alanine aminotransferase	27 (67.5)	1 (2.5)	28 (70)
Increased aspartate aminotransferase	24 (60)	1 (2.5)	25 (62.5)
Thrombocytopenia	9 (22.5)	1 (2.5)	10 (25)
Hypertension	12 (30)	0	12 (30)
Hand-foot skin reaction	13 (32.5)	2 (5)	15 (37.5)
Diarrhea	3 (7.5)	0	3 (7.5)
Hypothyroidism	5 (12.5)	0	5 (12.5)
Hyperthyroidism	1 (2.5)	0	1 (2.5)
Emaciation	6 (15)	0	6 (15)
Fever	10 (12.5)	0	10 (12.5)
Pain	19 (47.5)	0	19 (47.5)
Proteinuria	3 (7.5)	1 (2.5)	4 (10)
Elevated bilirubin	5 (12.5)	0	5 (12.5)
Autoimmune hemolytic anemia	0	1 (2.5)	1 (2.5)